Name: Is the combination of Velcade, Revlimid, and dexamethasone (VRd) helpful for myeloma patients over the age of 65?
Uploaded: 2019-02-14T09:26:33-0800
Duration: 3 min 27 s
Description: In this week’s video, Dr. Brian G.M. Durie discusses various trials that were presented at ASH and the triple therapy options that are available for myeloma patients of all ages. BOTTOM LINE: Triple therapies are wonderful options for healthy patients over the age of 65 and can produce excellent results.

In this week’s video, Dr. Brian G.M. Durie discusses various trials that were presented at ASH and the triple therapy options that are available for myeloma patients of all ages.

BOTTOM LINE:
Triple therapies are wonderful options for healthy patients over the age of 65 and can produce excellent results.

Have a question? Submit it to [email protected]

IMF Chairman Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected]!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at [email protected].

Image of Dr. Brian G.M. Durie Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.